Compare Abeona Therapeutics Inc (ABEO) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dolby Laboratories, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Dolby Laboratories, Inc. trades at $61.9 (market cap $5.82B). The key difference: Dolby Laboratories, Inc. is far larger — about 13.7× Abeona Therapeutics Inc's market cap, and Dolby Laboratories, Inc. pays a 2.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DLB | |
|---|---|---|
Market Cap | $424.33M | $5.82B |
Sector | Health | Industrials |
52-Week High | $7.45 | $75.62 |
52-Week Low | $4.17 | $48.51 |
Enterprise Value | $279.23M | $5.19B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Dolby Laboratories (DLB) trades at $61.77, up 1.4% today, with a bullish technical trend and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $0.69 versus $0.67 expected. Revenue remains stable around $1.3 billion annually, with robust gross margins of 87.61%. Recent news highlights growth in Dolby Atmos and automotive licensing, though near-term revenue volatility persists.
DLB offers a compelling valuation with a P/E of 26.29 below the analyst target of $87.50, implying significant upside. Key risks include licensing deal timing and competitive pressures in audio-video tech. Institutional sentiment is positive, with 47% of analysts rating it a Buy, but investors should monitor execution on Q4 growth guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
